Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Hum Genet ; 57(10): 665-9, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22854539

RESUMO

The objective of our present study was to develop a warfarin dosing algorithm for the Omani patients, as performances of warfarin dosing algorithms vary across populations with impact on the daily maintenance dose. We studied the functional polymorphisms of CYP2C9, CYP4F2 and VKORC1 genes to evaluate their impact on the warfarin maintenance dose in an admixed Omani patient cohort with Caucasian, African and Asian ancestries. We observed a 64-fold inter-patient variability for warfarin to achieve stable international normalized ratio in these patients. Univariate analysis revealed that age, gender, weight, atrial fibrillation, deep vein thrombosis/pulmonary embolism and variant genotypes of CYP2C9 and VKORC1 loci were significantly associated with warfarin dose in the studied patient population. However, multiple regression model showed that only the atrial fibrillation, and homozygous CYP2C9 variant genotypes (*2/*3 and *3/*3) and VKORC1 GA and AA genotypes remained significant. A multivariate model, which included demographic, clinical and pharmacogenetic variables together explained 63% of the overall inter-patient variability in warfarin dose requirement in this microgeographically defined, ethnically admixed Omani patient cohort on warfarin. This locally developed model performed much better than the International Warfarin Pharmacogenetics Consortium (IWPC) model as the latter could only explain 34% of the inter-patient variability in Omani patients. VKORC1 3673G>A polymorphism emerged as the single most important predictor of warfarin dose variability, even in this admixed population (partial R(2)=0.45).


Assuntos
Algoritmos , Farmacogenética/métodos , Varfarina/administração & dosagem , Adulto , Idoso , Hidrocarboneto de Aril Hidroxilases/genética , Fibrilação Atrial/tratamento farmacológico , Citocromo P-450 CYP2C9 , Sistema Enzimático do Citocromo P-450/genética , Família 4 do Citocromo P450 , Cálculos da Dosagem de Medicamento , Etnicidade/genética , Feminino , Estudos de Associação Genética , Loci Gênicos , Genética Populacional/métodos , Genótipo , Humanos , Modelos Lineares , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Oxigenases de Função Mista/genética , Omã/etnologia , Polimorfismo Genético , Estudos Prospectivos , Trombose Venosa/tratamento farmacológico , Vitamina K Epóxido Redutases
2.
Hum Biol ; 84(1): 67-77, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22452429

RESUMO

This is the first study to evaluate the spectrum and prevalence of dose-predictive genetic polymorphisms of the CYP2C9, CYP4F2 and VKORC1 loci together, in a geographically defined, ethnically admixed healthy adult Omani population sharing common lifestyle/environmental factors. Since the present-day Omani population is the result of an admixture of Caucasian, African and Asian ancestries, we compared the pharmacogenetic profile of these three loci in this population. Interestingly, the Omani pharmacogenetic profile, in terms of allele and genotype distribution, has values that are intermediate between Caucasians and African Americans, the African admixture further substantiated by the presence of the CYP2C9*8 allele. However, limitations and usefulness of such comparisons warrant caution, as the data from pharmacogenetic literature do not always represent bona fide population categories. Furthermore, definition of study population based on microgeographical scale would be more appropriate in pharmacogenetic research rather than the flawed racial, ethnic, or social categorizations since pharmacogenetic variation is clinal, and genetic influences will be further altered by lifestyle and environmental factors.


Assuntos
Anticoagulantes/farmacologia , Hidrocarboneto de Aril Hidroxilases/genética , Sistema Enzimático do Citocromo P-450/genética , Oxigenases de Função Mista/genética , Varfarina/farmacologia , Adulto , Hidrocarboneto de Aril Hidroxilases/metabolismo , Distribuição de Qui-Quadrado , Citocromo P-450 CYP2C9 , Sistema Enzimático do Citocromo P-450/metabolismo , Família 4 do Citocromo P450 , Feminino , Frequência do Gene , Genótipo , Humanos , Masculino , Oxigenases de Função Mista/metabolismo , Omã , Polimorfismo Genético , Prevalência , Vitamina K Epóxido Redutases
3.
Mediterr J Hematol Infect Dis ; 8(1): e2016013, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26977272

RESUMO

OBJECTIVES: Our aim was to study mannose-binding protein (MBP) polymorphisms in exonic and promoter region and correlate it with associated infections and vasoocculsive (VOC) episodes in sickle cell disease (SCD) patients since MBP plays an important role in innate immunity by activating the complement system. METHODS: We studied the genetic polymorphisms in the Exon 1 (alleles A/O) and promoter region (alleles Y/X; H/L, P/Q) of the MBL2 gene, in SCD patients as an increased incidence of infections is seen in these patients. A PCR-based, targeted genomic DNA sequencing of MBL2 was used to study 68 SCD Omani patients and 44 controls (healthy voluntary blood donors). RESULTS: In SCD patients, the frequency of the genotype related to the high production of MBL was 0.35 (YA/YA) and for intermediate/low production was 0.65 (YA/XA, XA/XA, YA/YO, XA/YO, YO/YO). The observed frequencies of MBL2 gene promoter polymorphism (-221, Y/X) were 44.4% and 20.5% for the heterozygous genotype Y/X and 3.2% and 2.2% for the homozygous (X/X) respectively between SCD patients and controls. MBL2 Exon1 gene mutations were 29.4% and 50% for the heterozygous genotype A/O and 5.9% and 6.8% respectively for the homozygous (O/O) genotype between SCD patients and controls. The distribution of variant MBL2 gene polymorphisms did not show any correlation in SCD patients with or without VOC attacks (p=0.16; OR -0.486; CI=0.177 -1.33), however, it was correlated with infections (p=0.0162; OR -3.55; CI 1.25-10.04). CONCLUSIONS: Although the frequency of the genotypes and haplotypes of MBL2 in SCD patients did not differ from controls, overall in the SCD patient cohort the increased representation of variant alleles was significantly correlated with infections (p<0.05). However, these variant MBL2 polymorphisms did not seem to play a significant role in the VOC episodes in this SCD cohort.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA